• Co-morbidity and drug treatment in Alzheimer’s disease. A cross sectional study of participants in the Dementia Study in Northern Norway 

      Andersen, Fred; Viitanen, Matti; Halvorsen, Dag; Straume, Bjørn; Engstad, Torgeir (Journal article; Tidsskriftartikkel; Peer reviewed, 2011)
      Inappropriate medical treatment of co-morbidities in Alzheimer’s disease (AD) is an increasing concern in geriatric medicine. The objective of this study was to compare current drug use related to co-morbidity between individuals with a recent diagnosis of AD and a cognitively healthy control group in a population based clinical trial in Northern Norway. Setting: Nine rural municipalities with ...
    • A community-based factorial trial on Alzheimer's disease. Effects of expectancy, recruitment methods, co-morbidity and drug use : The Dementia Study in Northern Norway. 

      Andersen, Fred (Doctoral thesis; Doktorgradsavhandling, 2011-10-21)
      Ni kommuner deltok i studien. I fem av kommunene fikk deltakerne med Alzheimers sykdom (AS) systematisk stimulering (n=103), i de resterende fire vanlig pleie og omsorg (n=84). Alle inkluderte ble randomisert dobbelt blindt til donepezil eller placebo, og fulgt med tre kognitive tester (MMSE, Klokketest og ADAS-Cog) hver fjerde måned i ett år. To testteknikere testet deltakerne på deres hjemsteder. ...
    • The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design 

      Andersen, Fred; Viitanen, Matti; Halvorsen, Dag; Straume, Bjørn; Wilsgaard, Tom; Engstad, Torgeir (Journal article; Tidsskriftartikkel; Peer reviewed, 2012)
      Progressive neurodegeneration in Alzheimer’s disease (AD) induces cognitive deterioration, and there is controversy regarding the optimal treatment strategy in early AD. Stimulation therapy, including physical exercise and cholinesterase inhibitors are both reported to postpone cognitive deterioration in separate studies. We aimed to study the effect of stimulation therapy and the additional effect ...
    • Evolusjon, rasebiologi og menneskeverd. Medisinens ubekvemme historie. 

      Andersen, Fred (Journal article; Tidsskriftartikkel, 2015-07)
    • Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk 

      Jansen, Iris E.; Savage, Jeanne E.; Watanabe, Kyoko; Bryois, Julien; Williams, Dylan M.; Steinberg, Stacy; Sealock, Julia; Karlsson, Ida K.; Hägg, Sara; Athanasiu, Lavinia; Voyle, Nicola; Proitsi, Petroula; Witoelar, Aree; Stringer, Sven; Aarsland, Dag; Almdahl, Ina Selseth; Andersen, Fred; Bergh, Sverre; Bettella, Francesco; Björnsson, Sigurbjörn; Brækhus, Anne; Bråthen, Geir; de Leeuw, Christiaan A.; Desikan, Rahul S.; Djurovic, Srdjan; Dumitrescu, Logan; Fladby, Tormod; Hohman, Timothy J.; Jónsson, Pálmi V.; Kiddle, Steven J; Rongve, Arvid; Saltvedt, Ingvild; Sando, Sigrid Botne; Selbæk, Geir; Shoai, Maryam; Skene, Nathan G.; Snædal, Jón G.; Stordal, Eystein; Ulstein, Ingun; Wang, Yunpeng; White, Linda Rosemary; Hardy, John; Hjerling-Leffler, Jens; Sullivan, Patrick; van der Flier, Wiesje M.; Dobson, Richard; Davis, Lea K; Stefánsson, Hreinn; Stefánsson, Kári; Pedersen, Nancy L; Ripke, Stephan; Andreassen, Ole Andreas; Posthuma, Danielle (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-07)
      Alzheimer’s disease (AD) is highly heritable and recent studies have identified over 20 disease-associated genomic loci. Yet these only explain a small proportion of the genetic variance, indicating that undiscovered loci remain. Here, we performed a large genome-wide association study of clinically diagnosed AD and AD-by-proxy (71,880 cases, 383,378 controls). AD-by-proxy, based on parental diagnoses, ...
    • Recruitment methods in Alzheimer's disease research : general practice versus population based screening by mail 

      Andersen, Fred; Engstad, Torgeir; Viitanen, M; Straume, Bjørn; Halvorsen, DS; Hykkerud, S; Sjobrend, K (Journal article; Tidsskriftartikkel; Peer reviewed, 2010)